Reneo Pharmaceuticals, Inc.

Scrip regularly covers business development and deal making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. AbbVie, Gilgamesh To Investigate Potent

Follow-on public offerings (FOPOs) have become increasingly difficult to execute in the current financial market climate with public biopharmaceutical company valuations plummeting, so many drug devel

Some three years after COVID-19 kickstarted a massive adoption of digital technology and shift to remote monitoring in clinical development, technology continues to effect seismic changes in the trial

With the US Inflation Reduction Act threatening a major shake-up in drug pricing from 2023 onwards, and with the progress of increasing numbers of costly advanced therapeutics onto the market, one thi